Displaying drugs 126 - 150 of 1617 in total
Sirna-027
Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth Factor Receptor-1(VEGFR-1). VEGFR-1 is a key component of the clinically validated vascular endothelial growth factor (VEGF) pathway. Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. It is used to treat Macular...
Investigational
Matched Name: … Sirna-027 …
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth …
Matched Description: … Sirna-027 is developed by Sirna Therapeutics and is under the phase I of clinical trails. ... Sirna-027 is a chemically modified short interfering RNA(siRNA) targeting Vascular Endothelial Growth …
CT-011
CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients with advanced haematological malignancies. It is directed against human PD-1 (programmed cell death 1; PDCD1), with immunomodulating and antitumor activities.
Investigational
Matched Name: … CT-011 …
Matched Description: … CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients …
Matched Description: … CT-011 is a humanized monoclonal antibody directed against a B7 family-associated protein, in patients …
NOV-002
NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy. NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim. It has been administered to over 10,000 patients, demonstrating clinical efficacy and excellent safety data.
Investigational
Matched Name: … NOV-002 …
Matched Description: … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim ... NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy …
Matched Description: … NOV-002 is approved and marketed in the Russian Fereration by Pharma BAM under the trade name Glutoxim ... NOV-002, the lead compound acts as a chemoprotectant and an immunomodulator, in combination with chemotherapy …
AGS-004
AGS-004 is a personalized RNA-loaded dendritic cellbased
immunotherapy that is designed to stimulate the patient’s immune system to target and destroy the patient’s own unique viral burden. Non-personalized HIV immunotherapies are unable to raise cytotoxic T lymphocytes against HIV antigens, fail to induce T cell memory, and, most importantly, do...
Investigational
Matched Name: … AGS-004 …
Matched Description: … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate …
Matched Description: … AGS-004 is a personalized RNA-loaded dendritic cellbased immunotherapy that is designed to stimulate …
ZEN-012
ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms of action: tubulin and topoisomerase II inhibition. ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties. It is developed for the treatment of solid tumors.
Investigational
Matched Name: … ZEN-012 …
Matched Description: … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms ... ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties …
Matched Description: … ZEN-012 is a novel small molecule and the first anti-cancer drug in development involving two mechanisms ... ZEN-012 also expresses additional modes of action such as pro-apoptotic and anti-angiogenic properties …
TLY-012
TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated TRAIL).
Investigational
Matched Name: … TLY-012 …
Matched Description: … TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated …
Matched Description: … TLY-012 is a PEGylated recombinant human tumor necrosis factor-related apoptosis-inducing ligand (PEGylated …
PAS-004
PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. It is being investigated for the treatment of neurofibromatosis 1 and Noonan syndrome.
Investigational
Matched Name: … PAS-004 …
Matched Description: … PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. …
Matched Description: … PAS-004 is an allosteric MEK 1/2 inhibitor being developed by Pasithea Therapeutics. …
VB2-011
VB2-011 is an antibody developed as an anti-cancer treatment. According to some preclinical studies, it has a potential to inhibit tumour growth in various cancers including lymphoma and melanoma. This drug includes the parent IgM (H11 IgM) and a recombinant IgG version (H11 IgG).
Investigational
Matched Name: … VB2-011 …
Matched Description: … VB2-011 is an antibody developed as an anti-cancer treatment. …
Matched Description: … VB2-011 is an antibody developed as an anti-cancer treatment. …
CZEN 002
CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating Hormone (a-MSH). CZEN-002 modulates inflammatory and immune responses. It has also been shown to kill Candida albicans (C. albicans), a single-celled fungal organism that causes a variety of infections, including vaginitis. This organism can invade tissues and produce fatal...
Investigational
Matched Name: … CZEN 002 …
Matched Description: … CZEN-002 modulates inflammatory and immune responses. ... It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. ... CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating …
Matched Description: … CZEN-002 modulates inflammatory and immune responses. ... It appears that CZEN-002 works on a receptor in yeast that has yet to be identified. ... CZEN-002 is a novel, non-azole anti-fungal synthetic octapeptide, derived from alpha-Melanocyte-Stimulating …
ETBX-011
ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen (CEA).
Investigational
Matched Name: … ETBX-011 …
Matched Description: … ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen …
Matched Description: … ETBX-011 is a cancer vaccine used to treat patients with cancers that express carcinoembryonic antigen …
ATX-01
ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b (miR-23b).
Investigational
Matched Name: … ATX-01 …
Matched Description: … ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b …
Matched Description: … ATX-01 is an antimiR, a chemically modified antisense oligonucleotide, designed to target microRNA 23b …
CEB-01
CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10-hydroxycamptothecin
Investigational
Matched Name: … CEB-01 …
Matched Description: … CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10 …
Matched Description: … CEB-01 is a biocompatible polymeric PLGA nanofiber membrane containing the active substance 7-ethyl-10 …
AVR-RD-04
AVR-RD-04 is an investigational gene therapy for cystinosis. It consists of autologous CD34+ enriched cells transduced with a lentiviral vector containing RNA resulting in codon-optimized cDNA encoding for functional human cystinosin.
Investigational
Matched Name: … AVR-RD-04 …
Matched Description: … AVR-RD-04 is an investigational gene therapy for cystinosis. …
Matched Description: … AVR-RD-04 is an investigational gene therapy for cystinosis. …
NP-G2-044
NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)).
Investigational
Matched Name: … NP-G2-044 …
Matched Description: … NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis ... Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)). …
Matched Description: … NP-G2-044 is under investigation in clinical trial NCT03199586 (Phase 1 Clinical Trial of Metastasis ... Inhibitor NP-G2-044 in Patients With Advanced or Metastatic Solid Tumors (Including Lymphoma)). …
ADL 10-0101
ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment of inflammatory pain, itch and visceral pain. Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at...
Investigational
Matched Name: … ADL 10-0101 …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
Matched Description: … ADL 10-0101 is a peripheral kappa opioid agonist analgesic product candidate. ... Preclinical trials of ADL 10-0101 have suggested that the compound may be effective for the treatment ... Because ADL 10-0101 does not cross the blood-brain barrier and enter the brain when administered at therapeutic …
AVR-RD-05
AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced ex vivo with a lentiviral vector encoding the human iduronate-2-sulfatase (IDS) enzyme. It is under investigation for the treatment of Hunter Syndrome (Mucopolysaccharidosis Type II, MPSII).
Investigational
Matched Name: … AVR-RD-05 …
Matched Description: … AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo …
Matched Description: … AVR-RD-05 is a gene therapy comprising genetically modified autologous stem cells transduced _ex vivo …
trans NV-04
trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial stiffness.
Investigational
Matched Name: … trans NV-04 …
Matched Description: … trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial …
Matched Description: … trans NV-04 is a cardiovascular drug which shows a significant reduction in blood pressure and arterial …
EMB-01
EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants With Advanced/metastatic Solid Tumors).
Investigational
Matched Synonyms: … Anti-egfr/c-met bispecific antibody emb-01 ... Anti-egfr/anti-c-met bispecific antibody emb-01 …
Matched Name: … EMB-01 …
Matched Description: … EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants …
Matched Name: … EMB-01 …
Matched Description: … EMB-01 is under investigation in clinical trial NCT03797391 (A Dose Escalation Study of EMB-01 in Participants …
VCN-01
VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20.
Investigational
Matched Name: … VCN-01 …
Matched Description: … VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20. …
Matched Description: … VCN-01 is an investigational, genetically modified human adenovirus encoding human PH20. …
Displaying drugs 126 - 150 of 1617 in total